Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Trial Details

NCT ID

NCT04519151

Phase

PHASE2

Sponsor

Sheba Medical Center

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• Pembrolizumab
• Lenvatinib

Locations (sample)

• Ramat Gan, Israel|32.08227,34.81065

Key Eligibility Criteria

• Female participants who are at least 18 years of age on the day of signing informed consent, with histologically-confirmed diagnosis of EOC (except…
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
• Not a woman of childbearing potential (WOCBP) OR
• A WOCBP who agrees to follow the contraceptive during the treatment period and for at least 120 days after the last dose of study treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.